Oncolytics Biotech (TSE:ONC) Insider Acquires C$34,928.00 in Stock

Oncolytics Biotech Inc. (TSE:ONC) insider Andrew Aromando bought 29,600 shares of the business’s stock in a transaction on Wednesday, February 11th. The shares were acquired at an average cost of C$1.18 per share, for a total transaction of C$34,928.00. Following the purchase, the insider directly owned 55,100 shares in the company, valued at C$65,018. This represents a 116.08% increase in their ownership of the stock.

Oncolytics Biotech Trading Down 1.3%

TSE:ONC opened at C$14.90 on Monday. The stock has a market cap of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. The business has a fifty day moving average of C$14.90 and a 200-day moving average of C$13.19. Oncolytics Biotech Inc. has a 1 year low of C$0.44 and a 1 year high of C$2.08. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99.

Oncolytics Biotech (TSE:ONC) last posted its quarterly earnings data on Wednesday, November 12th. The company reported C($0.14) earnings per share (EPS) for the quarter. Equities analysts predict that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.